IXICO plc (LON:IXI – Get Free Report)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 11.66 and traded as low as GBX 10.64. IXICO shares last traded at GBX 10.64, with a volume of 8,574 shares.
IXICO Stock Performance
The company has a debt-to-equity ratio of 3.32, a quick ratio of 4.90 and a current ratio of 2.85. The firm has a market capitalization of £10.10 million, a PE ratio of -5.89, a price-to-earnings-growth ratio of -0.38 and a beta of 0.86. The company’s fifty day moving average price is GBX 11.43 and its two-hundred day moving average price is GBX 11.66.
IXICO (LON:IXI – Get Free Report) last announced its quarterly earnings data on Tuesday, December 9th. The company reported GBX (1.85) earnings per share (EPS) for the quarter. IXICO had a negative net margin of 31.10% and a negative return on equity of 19.14%. As a group, equities analysts expect that IXICO plc will post -289.3584879 earnings per share for the current year.
IXICO Company Profile
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials.
Recommended Stories
- Five stocks we like better than IXICO
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- The Crash Has Already Started (Most Just Don’t See It Yet)
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for IXICO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IXICO and related companies with MarketBeat.com's FREE daily email newsletter.
